Literature DB >> 25124273

Metabolism in HD: still a relevant mechanism?

Wenzhen Duan1, Mali Jiang, Jing Jin.   

Abstract

The polyglutamine expansion within huntingtin is the causative factor in the pathogenesis of Huntington's disease (HD). Although the underlying mechanisms by which mutant huntingtin causes neuronal dysfunction and degeneration have not been fully elucidated, compelling evidence suggests that mitochondrial dysfunction and compromised energy metabolism are key players in HD pathogenesis. Longitudinal studies of HD subjects have shown reductions in glucose utilization before the disease clinical onset. Preferential striatal neurodegeneration, a hallmark of HD pathogenesis, also has been associated with interrupted energy metabolism. Data from genetic HD models indicate that mutant huntingtin disrupts mitochondrial bioenergetics and prevents adenosine triphosphate (ATP) generation, implying altered energy metabolism as an important component of HD pathogenesis. Here we revisit the evidence of abnormal energy metabolism in the central nervous system of HD patients, review our current understanding of the molecular mechanisms underlying abnormal metabolism induced by mutant huntingtin, and discuss the promising therapeutic development by halting abnormal metabolism in HD.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  AMPK; Huntington's disease; PGC-1α; energy metabolism; mitochondria; sirtuins

Mesh:

Substances:

Year:  2014        PMID: 25124273      PMCID: PMC4163071          DOI: 10.1002/mds.25992

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  109 in total

1.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

Review 2.  AMP-activated protein kinase signaling in metabolic regulation.

Authors:  Yun Chau Long; Juleen R Zierath
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

3.  SIRT2 regulates NF-κB dependent gene expression through deacetylation of p65 Lys310.

Authors:  Karin M Rothgiesser; Süheda Erener; Susanne Waibel; Bernhard Lüscher; Michael O Hottiger
Journal:  J Cell Sci       Date:  2010-11-16       Impact factor: 5.285

4.  Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.

Authors:  Ulziibat P Shirendeb; Marcus J Calkins; Maria Manczak; Vishwanath Anekonda; Brett Dufour; Jodi L McBride; Peizhong Mao; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2011-10-13       Impact factor: 6.150

5.  A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.

Authors:  Marianne R Smith; Adeela Syed; Tamas Lukacsovich; Judy Purcell; Brett A Barbaro; Shane A Worthge; Stephen R Wei; Giuseppe Pollio; Letizia Magnoni; Carla Scali; Luisa Massai; Davide Franceschini; Michela Camarri; Marco Gianfriddo; Enrica Diodato; Russell Thomas; Ozgun Gokce; S J Tabrizi; Andrea Caricasole; Bernard Landwehrmeyer; Liliana Menalled; Carol Murphy; Sylvie Ramboz; Ruth Luthi-Carter; Goran Westerberg; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-01-16       Impact factor: 6.150

6.  Evidence for a common mechanism of SIRT1 regulation by allosteric activators.

Authors:  Basil P Hubbard; Ana P Gomes; Han Dai; Jun Li; April W Case; Thomas Considine; Thomas V Riera; Jessica E Lee; Sook Yen E; Dudley W Lamming; Bradley L Pentelute; Eli R Schuman; Linda A Stevens; Alvin J Y Ling; Sean M Armour; Shaday Michan; Huizhen Zhao; Yong Jiang; Sharon M Sweitzer; Charles A Blum; Jeremy S Disch; Pui Yee Ng; Konrad T Howitz; Anabela P Rolo; Yoshitomo Hamuro; Joel Moss; Robert B Perni; James L Ellis; George P Vlasuk; David A Sinclair
Journal:  Science       Date:  2013-03-08       Impact factor: 47.728

7.  Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies.

Authors:  Luciano Merlini; Alessia Angelin; Tania Tiepolo; Paola Braghetta; Patrizia Sabatelli; Alessandra Zamparelli; Alessandra Ferlini; Nadir M Maraldi; Paolo Bonaldo; Paolo Bernardi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

8.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

9.  PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D S Markel; S Berent; B Giordani; R Ehrenkaufer; D Jewett; R Hichwa
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

10.  Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity.

Authors:  Wenjun Song; Jin Chen; Alejandra Petrilli; Geraldine Liot; Eva Klinglmayr; Yue Zhou; Patrick Poquiz; Jonathan Tjong; Mahmoud A Pouladi; Michael R Hayden; Eliezer Masliah; Mark Ellisman; Isabelle Rouiller; Robert Schwarzenbacher; Blaise Bossy; Guy Perkins; Ella Bossy-Wetzel
Journal:  Nat Med       Date:  2011-02-20       Impact factor: 53.440

View more
  16 in total

1.  Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.

Authors:  Joel D Federspiel; Todd M Greco; Krystal K Lum; Ileana M Cristea
Journal:  Mol Cell Proteomics       Date:  2019-04-30       Impact factor: 5.911

2.  Quantitative Proteomic Analysis Reveals Similarities between Huntington's Disease (HD) and Huntington's Disease-Like 2 (HDL2) Human Brains.

Authors:  Tamara Ratovitski; Raghothama Chaerkady; Kai Kammers; Jacqueline C Stewart; Anialak Zavala; Olga Pletnikova; Juan C Troncoso; Dobrila D Rudnicki; Russell L Margolis; Robert N Cole; Christopher A Ross
Journal:  J Proteome Res       Date:  2016-08-03       Impact factor: 4.466

Review 3.  Mitochondrial Abnormalities and Synaptic Damage in Huntington's Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics.

Authors:  Neha Sawant; Hallie Morton; Sudhir Kshirsagar; Arubala P Reddy; P Hemachandra Reddy
Journal:  Mol Neurobiol       Date:  2021-09-14       Impact factor: 5.590

Review 4.  Metabolic control of the proteotoxic stress response: implications in diabetes mellitus and neurodegenerative disorders.

Authors:  Kuo-Hui Su; Chengkai Dai
Journal:  Cell Mol Life Sci       Date:  2016-06-11       Impact factor: 9.261

5.  Post-translational modifications clustering within proteolytic domains decrease mutant huntingtin toxicity.

Authors:  Nicolas Arbez; Tamara Ratovitski; Elaine Roby; Ekaterine Chighladze; Jacqueline C Stewart; Mark Ren; Xiaofang Wang; Daniel J Lavery; Christopher A Ross
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

Review 6.  Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism.

Authors:  Pauline Vercruysse; Didier Vieau; David Blum; Åsa Petersén; Luc Dupuis
Journal:  Front Mol Neurosci       Date:  2018-01-19       Impact factor: 5.639

Review 7.  Mechanisms of Metal-Induced Mitochondrial Dysfunction in Neurological Disorders.

Authors:  Hong Cheng; Bobo Yang; Tao Ke; Shaojun Li; Xiaobo Yang; Michael Aschner; Pan Chen
Journal:  Toxics       Date:  2021-06-17

Review 8.  Purine Nucleotides Metabolism and Signaling in Huntington's Disease: Search for a Target for Novel Therapies.

Authors:  Marta Tomczyk; Talita Glaser; Ewa M Slominska; Henning Ulrich; Ryszard T Smolenski
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

Review 9.  Glucose metabolic crosstalk and regulation in brain function and diseases.

Authors:  Shuai Zhang; Brittany Bolduc Lachance; Mark P Mattson; Xiaofeng Jia
Journal:  Prog Neurobiol       Date:  2021-06-10       Impact factor: 10.885

10.  Potential biomarkers to follow the progression and treatment response of Huntington's disease.

Authors:  Marie-Hélène Disatnik; Amit U Joshi; Nay L Saw; Mehrdad Shamloo; Blair R Leavitt; Xin Qi; Daria Mochly-Rosen
Journal:  J Exp Med       Date:  2016-11-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.